SPAC Nocturne Acquisition Corp. (NASDAQ:MBTC) plans to merge with Cognos Therapeutics for $120M in Nocturne stock, subject to certain adjustments.
The deal is expected to close in Q2 or Q3, according to the companies.
Based in Inglewood, Calif., Cognos has been developing medical technologies to treat blood and spinal cancers and neurological disorders such as Alzheimer’s and Parkinson’s. The company’s lead product, the Sinnais Implantable Smart Pump system, is designed to more effectively deliver treatments to targeted tissues in patients with brain cancer.
Nocturne held its initial public offering in April 2021, raising $100M.
For more SPAC news, check out SA’s SPAC News page.